News

News and Press Releases
Research | About the CF Foundation | Our Research Approach CF Foundation Funds Three New Research Awards to Advance its Path to a Cure Initiative

New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations

| 5 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Invests Up to $8.4M in SpliSense for the Development of Potential Rare Mutation Therapy

Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.

| 4 min read
Research Molecular Analysis Identifies Key Differences in Lungs of People With Cystic Fibrosis

Researchers' catalog of airway cell types could reveal targets for future genetic therapies

| 6 min read
Advocacy | About the CF Foundation CF Foundation Responds to NIH Call for Information on Diversity and Inclusion

The Cystic Fibrosis Foundation recently submitted comments to the National Institutes of Health on improving racial equity, diversity, and inclusion in the biomedical research workforce.

| 2 min read
About the CF Foundation William Skach, Chief Scientific Officer, to Retire From the CF Foundation

William Skach, MD, Chief Scientific Officer, will retire from the CF Foundation this summer.

| 2 min read
About the CF Foundation | Fitness CF Foundation Extends Collaboration With Exercise and Wellness Platform Beam Through 2021

The Cystic Fibrosis Foundation has renewed its commitment to supporting the health and well-being of adults living with cystic fibrosis by supporting free access to the online exercise, education, and well-being platform, Beam.

| 3 min read
Coronavirus (COVID-19) CF Foundation Reaffirms Support for COVID-19 Vaccination for People Living With Cystic Fibrosis

FDA issues emergency use authorization for a third COVID-19 vaccine.

| 2 min read
Research | Drug Pipeline | Medications FDA Accepts Vertex Application for Expansion of Trikafta to Include Children ages 6-11

Today, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted its application to expand Trikafta® (elexacaftor/tezacaftor/ivacaftor) to include children ages 6-11 years old with cystic fibrosis who have at least one F508del or a mutation in the CFTR gene that is responsive based on in vitro data. The FDA has granted priority review of the application and has indicated that it will make a decision by June 8, 2021. 

| 2 min read
Coronavirus (COVID-19) CF Foundation Strongly Supports COVID-19 Vaccine Recommendations for People Living With Cystic Fibrosis

On Thursday, January 14 at 7 p.m. ET the CF Foundation will host a live town hall where top questions about the COVID-19 vaccines will be answered by a panel of experts. Register here.

| 2 min read